ADVFN ADVFN

Hot Features

Icon for monitor ブラジル証券取引所、NASDAQ、NYSE、AMEX、LSEなどの主要取引所からの複数のリアルタイム株価を監視します。
AgomAb Therapeutics NV

AgomAb Therapeutics NV (AGMB)

13.81
0.38
(2.83%)
終了 6月28日 5:00AM
13.91
0.10
(0.72%)
取引時間後: 8:59AM

AgomAb Therapeutics NV (AGMB) 銘柄情報

ポートフォリオを強化: リアルタイムのディスカッションと実用的な取引アイデア。

プレミアム

主要統計と詳細

通貨
13.81
( 2.83% )
買値
5.22
売値
14.50
出来高
96,415
12.4989 日の範囲 14.06
8.75 52 週間の範囲 17.4528
時価総額
前日終値
13.43
始値
12.82
最終取引時間
財務取引量
US$ 1,253,525
VWAP
13.0013
平均取引量 (3 か月)
US$ 138,953
発行済株式数
49,247,975
配当利回り
PER
-0.07
1 株当たり利益 (EPS)
-143.22
歳入
-
純利益
-62.55M

AgomAb Therapeutics NV について

AgomAb Therapeutics NV, a clinical-stage biopharmaceutical company, develops novel disease-modifying therapies for immunology and inflammatory diseases in the United States. The company’s product pipeline includes Ontunisertib (AGMB-129), an oral gastrointestinal-restricted small molecule inhibitor ... AgomAb Therapeutics NV, a clinical-stage biopharmaceutical company, develops novel disease-modifying therapies for immunology and inflammatory diseases in the United States. The company’s product pipeline includes Ontunisertib (AGMB-129), an oral gastrointestinal-restricted small molecule inhibitor of ALK5 or TGFßR1 for the treatment of Fibrostenosing Crohn’s disease, which is in Phase 2a clinical trials; and AGMB-447, an inhaled small molecule inhibitor of ALK5 or TGFßR1 for the treatment of idiopathic pulmonary fibrosis that is in Phase 1 clinical trials. It also develops AGMB-101, a HGF-mimetic monoclonal antibody that acts through agonism or stimulation of the MET receptor and has demonstrated antifibrotic and regenerative activity in preclinical models. The company was incorporated in 2017 and is headquartered in Antwerp, Belgium. 詳細を表示

セクター
-
業界
-
ウェブサイト
本社
Antwerp, Belgium
設立
2026
AgomAb Therapeutics NV is listed in the sector of the ナスダック市場 with ticker AGMB. The last closing price for AgomAb Therapeutics NV was US$13.43. Over the last year, AgomAb Therapeutics NV shares have traded in a share price range of US$ 8.75 to US$ 17.4528.

AgomAb Therapeutics NV currently has 49,247,975 shares in issue. The market capitalisation of AgomAb Therapeutics NV is US$680.11 million. AgomAb Therapeutics NV has a price to earnings ratio (PE ratio) of -0.07.

AGMB 最新ニュース

期間 †前日比前日比 %始値高値安値平均出来高VWAP
12.8926.465201465210.921410.62511838212.52036528DR
42.4321.353251318111.38148.7511598610.91226771DR
123.128.944911297910.71148.7511955810.99418823DR
26-0.74-5.0859106529214.5517.45288.7513929512.35371366DR
52-0.74-5.0859106529214.5517.45288.7513929512.35371366DR
156-0.74-5.0859106529214.5517.45288.7513929512.35371366DR
260-0.74-5.0859106529214.5517.45288.7513929512.35371366DR

AGMB - Frequently Asked Questions (FAQ)

What is the current AgomAb Therapeutics NV share price?
The current share price of AgomAb Therapeutics NV is US$ 13.81
How many AgomAb Therapeutics NV shares are in issue?
AgomAb Therapeutics NV has 49,247,975 shares in issue
What is the market cap of AgomAb Therapeutics NV?
The market capitalisation of AgomAb Therapeutics NV is USD 680.11M
What is the 1 year trading range for AgomAb Therapeutics NV share price?
AgomAb Therapeutics NV has traded in the range of US$ 8.75 to US$ 17.4528 during the past year
What is the PE ratio of AgomAb Therapeutics NV?
The price to earnings ratio of AgomAb Therapeutics NV is -0.07
What is the registered address of AgomAb Therapeutics NV?
The registered address for AgomAb Therapeutics NV is Posthoflei 1/6, Antwerp, Antwerp, 2600
What is the AgomAb Therapeutics NV website address?
The website address for AgomAb Therapeutics NV is www.agomab.com

AGMB 取引

さらに

取引は遅延しています

リアルタイムの取引を取得するには、アカウントをアップグレードしてください

リアルタイムにアップグレード

最近閲覧した銘柄

Delayed Upgrade Clock